Alector Inc ALEC

$2.54 +0.09 (3.67%)

Valuation

Market cap
273,560,000
Revenue TTM
$21,050,000
Net income TTM
$-142,930,000
P/E (trailing)
7.51
P/E (forward)
5.52
Profit margin
-679.00%
Debt to equity
0.00

Trading

Volume
1,799,100
Avg volume
3,900,182
Day's range
$2.30 – $2.59
Shares out
111,657,000
Stochastic %K
63%
Beta
0.61
Analysts
Moderate Buy
Price target
$3.90

Price

Company profile

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL0...

Show more

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.

Industry
Biotechnology
Sector
Healthcare
Phone
415 231 5660
Website
https://www.alector.com
Address
131 Oyster Point Boulevard, Suite 600, South San Francisco, United States

Latest news

Stocktwits

notreload_ai Nov 13, 12:50 PM
Wells Fargo initiates $ALEC with an Overweight rating and $7 price target, citing its brain carrier platform and Alzheimer’s drug AL-137. https://notreload.xyz/xy/alector-gets-overweight-initiation-from-wells-fargo-on-alzheimers/
0 replies
TwitoTreat Nov 12, 2:43 PM
$ALEC back down to 2? or a pull back? This stock has been real fun trading between 1.8-2.7... wondering what happens now
0 replies
1234counting Nov 11, 8:36 PM
$ALEC will this hit 3 tomorrow realistically?
0 replies
TwitoTreat Nov 9, 6:41 PM
$ALEC
0 replies
cloudforever Nov 9, 6:22 PM
$ALEC gotta break 2.6 resistance
0 replies
Cornlikker Nov 9, 1:14 PM
$ALEC Little to no volume this will sit around 2.00. Need some positive news soon.
0 replies
GTA_Terminal Nov 9, 12:31 PM
Dark pool check on $ALEC: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Read the full article for the full details: https://globaltradersacademy.com/articles/alector-alec-technical-levels-options-flow-dark-pools-line-up-above-2-06?utm_source=stocktwits&utm_medium=social
0 replies
CC123italy Nov 6, 8:49 PM
$ALEC
0 replies